RTW Venture Fund Ltd - New York-based investor in life sciences, biopharmaceutical, and medical technology companies - Takes part in Series B financing round worth USD85 million into Kyverna Therapeutics Inc.
Kyverna is a cell therapy firm which is developing a new class of therapies for autoimmune and inflammatory disease.
Proceeds from the funding round will go towards the initiation of a phase two clinical trial for the company's lead asset KYV-101, scheduled for the first half of 2022.
Current stock price: USD1.50
12-month change: down 32%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Rtw Biotech (RTW)